bullish
China Healthcare Weekly (Dec.16) - ICU Expansion, Abnormal Medical Demand, Dying Chapter 18A of HKEX
446 Views18 Dec 2022 09:17
Investor should treat ICU expansion rationally due to staff shortage. Demand during COVID was abnormal, which may have natural growth in 23H2. IPO under Chapter 18A won't be main exit channel of PE/VC
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 4-minute read)
Discussions
(Paid Plans Only)
Top 5%
Xinyao (Criss) Wang
HK/China Healthcare Analyst (ex-Fosun Pharma)
- Merck Puts Eye-Popping $9.3B in ADC Deal with Kelun - The "New Story" Is About to Begin27 Dec 2022
- China Healthcare Weekly (Dec.25) - OK Lens VBP, Angelalign, Extraordinary 2022 for Pharmaceuticals26 Dec 2022
- Interpretation of China’s Central Economic Work Conference for 202320 Dec 2022
- China Healthcare Weekly (Dec.16) - ICU Expansion, Abnormal Medical Demand, Dying Chapter 18A of HKEX18 Dec 2022
- Alibaba Health Information Technology (241.HK) FY23H1 - Concerns Behind the Performance Turnaround15 Dec 2022
- China Healthcare Weekly (Dec.9) - COVID Policy Update, Biotech Growth Curve, HKEX Chapter 18A Review11 Dec 2022
- China Healthcare Weekly (Dec.2)- VBP Correction, Sales Ability Overweigh R&D, Expectation Difference04 Dec 2022
x